Rewriting Rare Disease R&D with Foundation Models

Drug development has long been a costly, trial-and-error effort, with nine out of ten clinical programs failing despite major scientific advances. One reason is that biological information remains fragmented in silos, and traditional R&D approaches often rely on narrow, task-specific datasets. Bioptimus aims to change this by using AI to build a foundation model that integrates multimodal, multiscale biological data into a single body of knowledge. The approach has particular promise for rare diseases, where patient numbers and data are scarce, preclinical models are poor, and development economics are challenging. We spoke with Jean-Philippe Vert, co-founder and CEO of Bioptimus, about the inherent messiness of biology, the potential to transform rare disease drug development with a foundation model, and how uncovering similarities between conditions could enable repurposing of existing drugs.

You can listen to Rewriting Rare Disease R&D with Foundation Models online on Radio and Podcast. Open the player on this page to stream the available audio.

Rewriting Rare Disease R&D with Foundation Models is an episode from RARECast by RARECast.

This episode is 00:26:30 long.

This episode was published on Feb 5, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from RARECast when more episodes are available from the podcast feed.